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ABSTRACT
Osteotropic Cytokines mediate human osteoblast-like cell eicosanoid
production.

Anurag Grover

Because of its high incidence and devastating socio-economic consequences,
osteoporosis is an important disorder of the aging population. To treat and to prevent
this disorder the basic physiological mechanisms regulating bone cell biology must
be understood. Bone remodeling is regulated by systemic hormones such as
parathyroid hormone, glucocorticoids, estrogen, 1,25-dihydroxyvitamin D3
(1,25(OH) 2 D3), and by local factors such as cytokines, growth factors, and
prostaglandins, which affects cells of the osteoclast or osteoblast lineage.
The regulation of bone metabolism by hormones has been extensively studied, but it
is now clear that locally produced, nonsystemic, autocrine and paracrine factors play
a direct and important role in bone remodeling. Eicosanoids (e.g. prostaglandins,
HETEs, leukotrienes) are key components of a target cell’s early responses to
various stimulators including growth factors, cytokines, and hormones.
We have examined the effects of the cytokines tumor necrosis factorα (TNF),
transforming growth factorβ (TGFβ) and the effect of cyclooxygenase inhibitor
ibuprofen on prostaglandin and 15-HETE biosynthesis by normal adult human
osteoblast-like (hOB) cells. In the present studies, conditioned media harvested from
hOB cell cultures were assayed by eicosanoid specific EIAs to determine
quantitatively the effects of cytokines on PGE2, 6-keto-PGF1α, PGF2α, PGD2,
thromboxane (TXB2) and on 15-HETE biosynthesis. EIA analysis indicated that
PGE2 was the predominant PG metabolite released by unstimulated hOB cells and its
synthesis was increased more than other PGs in cells treated with TGFβ and TNFα,
both separately and in combination. TXB2 was not detected in control samples, or in
samples stimulated with cytokines. 15-HETE was produced by the hOB cells, and
was sensitive to modulation by the cytokines and ibuprofen.
The possibility that the up-regulation of PGE2 synthesis elicited by cytokines
might have resulted from an increased level of the terminal PGE2 synthases (cPGES
and mPGES) was tested. Transcripts for cPGES and mPGES was assessed by the
reverse-transcriptase polymerase chain reaction using specific primers for human
cPGES and mPGES. Upon dual cytokine stimulation, a significant up-regulation of
cPGES and mPGES mRNA was observed.
The steady-state level of 15-Lipoxygenase type-II mRNA in the hOB cells
was determined in control samples and specimens treated with TGFβ and/or TNFα,
IL-3 and IL-1β. A significant increase in 15-LOX type-II mRNA level was evident
in specimens treated with TNFα alone (47.9 ± 22 fold-basal).
Thus, these studies indicate that TGFβ and/or TNFα modulate AA metabolism
and upregulation of PGE2 synthesis elicited by these cytokines might have resulted
from an increased level of the terminal PGE2 synthases in hOB cells.
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INTRODUCTION
Osteoporosis is a skeletal disorder in which bone strength is compromised
due to the loss of bone density and bone quality (Inzerillo et al., 2002). It is
characterized by low bone mass as well as by the micro architectural deterioration of
bone with a consequent increase in bone fragility and sensitivity to fractures
following minimal trauma (Riggs et al., 1992). Efforts have been primarily
concentrated on the development of drugs that block bone resorption by decreasing
the formation of osteoclasts or the activity of the osteoclasts. Inhibition of bone
resorption can be accomplished by reducing either osteoclast generation (with
estrogen or selective estrogen receptor modulators) or osteoclast activity (with
calcitonin or bisphosphonates) (Stepan et al., 2003). Parathyroid hormone has
become available as the first anabolic agent that increases bone formation (Hodsman
et al., 1997). To date, these drugs and hormones have been the backbone of
osteoporosis treatment and the prevention of fractures (Allen, 1993, Prestwood et al.,
1998).
Notwithstanding the available effective therapies, osteoporosis is the most
commonly occuring bone disease, and it is expected that the prevalence of
osteoporosis will increase as the population ages (Fontanges et al., 2004). It affects
approximately 28 million people in the United States, mostly post menopausal
women, due to an accelerated rate of bone loss at and following the menopause
(Hightower, 2000). Among significant chronic ailments in the U.S., 28 million
people are affected with osteoporosis compared with 52 million and 42 million
afflicted by hypercholesterolemia and by hypertension, respectively (Natarajan et al.,
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2003). Health care costs of fractures resulting from osteoporosis were estimated to
be $10 to $18 billion per year in the U.S.A in 1997, and these costs are predicted to
grow to more than $60 billion per year by the year 2020 (Ray et al., 1997).
Bone is a dynamic living tissue that protects the body’s internal organs,
provides sites for muscle attachment for locomotion, and serves such physiological
functions as maintaining calcium and phosphate balances in the body, and providing
a site for the production of haemopoietic tissues (Rho et al., 2004). In adults, bone
undergoes a continous process of remodeling, that is, the replacing of old and
damaged bone with newly formed bone (Eriksen et al., 1994; Jilka et al., 1994).
Osteoporosis results from defective bone remodeling regulation: the main problem is
an imbalance between the rates of bone resorption and bone formation such that
resorption exceeds formation particularly in cancellous bone (Raisz et al., 1984). In
adults, approximately 25% of cancellous bone is resorbed and replaced every year,
as compared with only 3% of cortical bone (Seeman, 2003). Cancellous bone has a
high surface-to-volume ratio with 70 to 85% of the surface of the trabecular bone in
contact with the bone marrow (Islam et al., 1990). In addition to their anatomical
concurrence, cells of the bone and the haemopoietic bone marrow share progenitors,
produce and respond to some of the same cytokines and colony-stimulating factors,
and are ultimately essential for each other’s function (Prockop, 1997).
Bone is composed of four different cell types (Fig. 1.). Osteoblasts,
osteoclasts, and bone lining cells are present on bone surfaces, whereas osteocytes
permeate the mineralized interior. Osteoblasts, lining cells, and osteocytes are all
cells of the osteoblast lineage and osteoclasts are derived from precursors originating

2

in the bone marrow (Manolagas et al., 1995; Manolagas et al., 1995). The precursors
of osteoblasts are multipotent mesenchymal stem cells, which also give rise to bone
marrow stromal cells, chondrocytes, muscle cells, and adipocytes (Owen, 1985;
Ghilzon et al., 1999; Hirschi et al., 2002) whereas the precursors of osteoclasts are
hematopoietic cells of the monocyte/macrophage lineage (Vaes, 1988; Suda et al.,
1992; Roodman, 1996). Long before osteoblasts could be cultured, the existence of
multipotent mesenchymal stem cells was suspected, based on the evidence that
fibroblastic colonies formed in cultures of adherent bone marrow cells can
differentiate, under suitable stimuli, into each of the above mentioned cells; these
progenitors were named colony forming unit fibroblasts (CFU-F) (Castro-Malaspina
et al., 1984; Pittenger et al., 1999). When CFU-F are cultured in the presence of βglycerophosphate and ascorbic acid, the majority of the colonies form a mineralized
bone nodule; these bone-forming colonies are known as CFU-osteoblast (CFU-OB)
(McCulloch et al., 1991; Malaval et al., 1994). Osteoblast precursors may originate
not only from stromal mesenchymal progenitors of the marrow, but also from
pericytes, mesenchymal cells that are adherent to the endothelial layer of blood
vessels penetrating bone tissue (Schor et al., 1995). Whereas osteoclast precursors
reach bone from the circulation, osteoblast precursors most probably reach bone by
the migration of progenitors from neighboring connective tissues (Manolagas, 2000).
Fully differentiated osteoblasts produce and secrete proteins that make up the
organic phase of bone matrix (Rifas et al., 1989). The proteinaceous matrix is
subsequently mineralized under the control of the same cells (Masi et al., 2001;
Mulari et al., 2004). A major protein product of the bone-forming osteoblast is type

3

I collagen and it is a useful bone-formation marker (Abildgaard et al., 2004). This
polymeric protein is initially secreted in the form of a precursor, which contains
peptide extensions at both the amino-terminal and the carboxyl end of the molecule.
The propeptide extensions are proteolytically removed. Further extracellular
processing results in mature three-chained type I collagen molecules, which then
assemble themselves into a collagen fibril (Imamura et al., 1998). Individual
collagen molecules become interconnected by the formation of pyridinoline crosslinks, which are unique to bone (Hanson et al., 1992). Bone-forming osteoblasts
synthesize a number of other proteins that are incorporated into the bone matrix,
including osteocalcin and osteonectin, which constitute 40% to 50% of the noncollagenous proteins of bone (Rodan et al. 1991). Osteocalcin (OC) is widely used
as a marker for in vivo osteoblastic activity and bone formation (Gerdhem et al.,
2004). Mice deficient in osteocalcin develop a phenotype characterized by higher
bone mass and improved bone quality, suggesting that osteocalcin functions
normally to limit bone formation without compromising mineralization (Ducy et al.,
1996). Osteonectin may mediate deposition of hydroxyapatite and binds growth
factors (Termine et al., 1981; Delany et al., 1998). Mice deficient in osteonectin
exhibit decreased osteoclast and osteoblast numbers and reduced bone remodeling
suggesting that under normal conditions osteonectin may play a role in the birth or
survival of these cells (Delany et al., 2000). A number of other minor proteins such
as osteopontin, bone sialoprotein, fibronectin, vitronectin, and thrombospondin serve
as attachment factors that interact with integrins (Grzesik et al., 1994). In addition to
being the cells that produce the osteoid matrix, mature osteoblasts are essential for its
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mineralization, the process whereby deposition of hydroxyapatite crystals occurs
(Hessle et al., 2002). Osteoblasts are thought to regulate the local concentrations of
calcium and phosphate in such a way as to promote formation of hydroxyapatite
crystals (Boskey, 1996; Boskey, 1998). Mineralization of the matrix increases the
density of bone by displacing water, but does not alter its volume (Robinson et al.,
1957; Neuman et al., 1958). Osteoblasts express very high amounts of alkaline
phosphatase, which is anchored to the outer surface of the plasma membrane (Stein
et al., 1993). Alkaline phosphatase has been long thought to play a role in bone
mineralization. Consistent with this, deficiency of alkaline phosphatase due to
genetic defects leads to a condition hypophosphatasia characterized by defective
bone mineralization (Whyte, 1994; Wennberg et al., 2000). However, the precise
mechanism of mineralization and the exact role of alkaline phosphatase in this
process remain ambiguous.
Mature osteoclasts are usually large (50 to 100 µm diameter), multinucleated
cells with abundant mitochondria, numerous lysosomes, and free ribosomes. They
are usually found in contact with a calcified bone surface and within lacunae that are
the result of their own resorptive activity. Their most remarkable morphological
feature is the ruffled border, a complex system of finger-shaped projections of the
membrane, the function of which is to support the resorption of the calcified bone
matrix (Roodman, 1996; Boskey, 1998). This structure is completely surrounded by
another specialized area, called the clear zone. The clear zone delineates the area of
attachment of the osteoclast to the bone surface and seals off a distinct area of the
bone surface, essentially forming a secondary lysosome, that lies immediately
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underneath the osteoclast, that will be acidified and excavated. The ability of the
clear zone to seal off this area of bone surface allows the formation of an acidic
microenvironment suitable for the operation of the resorptive apparatus.
Acidification of the secondary lysosome is created by the action of an ATPdriven proton pump located in the ruffled border membrane. The mineral component
of the matrix is dissolved in the acidic environment of the resorption site. The
protein components of the matrix, mainly collagen, are degraded by matrix
metalloproteinases and cathepsins that are secreted by the osteoclast into the area of
bone resorption (Bossard et al., 1996). The degraded bone matrix components are
endocytosed along the ruffled border within the resorption lacunae and transcytosed
to the membrane area opposite the bone, where they are released (Salo et al., 1997).
Active osteoclasts exhibit a characteristic polarity, that is, the nuclei of the
osteoclasts are typically located in the part of the cell most removed from the bone
surface and are interconnected by cytoskeletal proteins (Watanabe et al., 1995).
Another characteristic of osteoclasts is the presence of high amounts of the
phosphohydrolase enzyme, tartrate-resistant acid phosphatase (TRAPase). This
aspect is widely used as marker for osteoclasts in bone specimens (Udagawa et al.,
1990; Hayman et al., 1996).
Some mature osteoblasts are ultimately buried within refilled lacunae of
mineralized matrix, and these buried cells are responsible for maintainence of matrix
(Buckwalter et al., 1996). These cells are the osteocytes and are characterized by a
striking stellate morphology, resembling the dendritic network of the nervous system
(Marotti et al., 1990; Nijweide et al., 1996). Osteocytes are regularly spaced
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throughout the mineralized matrix and communicate with each other and with
osteoblasts, which in turn communicate with cells of the bone marrow stroma (Fig.
1.). A syncytium extends from the entombed osteocytes all the way to the blood

Figure 1. Functional syncytium comprising osteocytes, osteoblasts, bone marrow
stromal cells, and endothelial cells. [Adapted from Journal of Clinical Investigation
104:1363–1374, 1999.]
vessel wall (Marotti et al., 1996). Consequenly, the strategic location of osteocytes
makes them excellent candidates for mechanosensory cells able to detect the need for
bone augmentation or reduction during functional adaptation of the skeleton, and the
need for repair of microdamage. The disruption of the osteocyte network would be
likely to increase bone fragility (Weinstein et al., 1998; Tomkinson et al., 1998).
Bone lining cells are flat, elongated, dormant cells that cover bone surfaces that are
undergoing neither bone formation nor resorption (Parfitt, 1994).
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During development and growth, the skeleton is sculpted to achieve its shape
and size by the removal of bone from one site and deposition at a different one; this
process is called modeling. Once the skeleton has reached maturity, regeneration
continues in the form of a periodic replacement of old bone with new at the same
location (Frost, 1973). This process is called remodeling and is responsible for the
complete renewal of the adult skeleton every 10 years. The purpose of remodeling in
the adult skeleton is not entirely clear, although in bones that are load bearing
remodeling most likely serves to repair fatigue damage and to prevent excessive
aging and its consequences. Therefore, the most likely function of bone remodeling
is to prevent the accumulation of old or damaged bone.
Removal of bone i.e., resorption, is the task of osteoclasts, while formation of
new bone is the function of osteoblasts. Bone resorption and bone formation are not
independently regulated processes (Parfitt, 1984). In the uninjured adult skeleton, all
osteoclasts and osteoblasts belong to a unique transitory structure, known as a basic
multicellular unit or BMU (Parfitt, 1994). Although during modeling one cannot
distinguish anatomical units analogous to the BMU by itself, sculpting of the
growing skeleton requires spatial and sequential orchestration of the destination of
osteoblasts and osteoclasts, although with different rules and coordinates to those
operating in the BMU of the remodeling skeleton. The BMU in cortical bone is
approximately 1–2 mm long and 0.2–0.4 mm wide, comprises a team of osteoclasts
in the front, a team of osteoblasts in the back, a central vascular capillary, a nerve
supply, and associated connective tissue (Parfitt, 1994). In healthy human adults, it
is estimated that 3–4 million BMUs are initiated per year and about 1 million are
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operating at any moment. Each BMU begins at a particular place and time
(origination) and advances toward a target, which is a region of bone in need of
replacement, and for a variable distance beyond its target (progression) and
eventually comes to rest (termination) (Parfitt, 1996). Osteoclasts adhere to bone
and subsequently remove it by acidification and proteolytic digestion. As the BMU
advances, osteoclasts leave the resorption site and osteoblasts move in to cover the
excavated area and begin the process of new bone formation by secreting osteoid,
which is eventually mineralized into new bone.
Table 1. Vital statistics of adult bone remodeling (Parfitt, 1994).
• Lifespan of BMU - 6–9 months
• Speed - 25µm/day
• Bone volume replaced by a single BMU - 0.025 mm3
• Lifespan of osteoclasts - 2 weeks
• Lifespan of osteoblasts (active) - 3 months
• Interval between successive remodeling events at the same location - 2–5 years.
• Rate of turnover of whole skeleton - 10% per year

The lifespan of the BMU is 6–9 months, which is much longer than the lifetime of its
constituent cells (Table 1). As a result, a continuous supply of new osteoclasts and
osteoblasts derived from their respective progenitors in the bone marrow is essential
for the origination of BMUs and their progression on the bone surface.
Consequently, the balance between the supply of new cells and their lifespan are key
determinants of the number of either cell type in the BMU and the work performed
by each type of cells which is significant for the maintenance of bone homeostasis.
"Remodeling" of bone begins early in fetal life, and once the skeleton is fully
formed in young adults, most of the skeletal metabolic activity is in this form
9

(Eriksen, 1986; Erlebacher et al., 1995; Reddi, 1997). The bone remodeling cycle
involves a series of highly regulated steps (Fig. 2.) that depend on the interactions of
the osteoblastic cells and the osteoclastic cells (Raisz et al., 1983; Raisz, 1999). The
initial "activation" stage involves the interaction of osteoclast and osteoblast

Fig. 2. Bone remodeling: Remodeling begins with attraction of osteoclasts to the
target site, probably triggered by mechanical stimuli or release of chemotactic
substances from areas of microdamage in bone. Mature osteoclasts remove bone
during the phase of bone resorption. After resorption is complete, osteoclasts
undergo apoptosis during the reversal phase, and bone formation begins as
osteoblasts are recruited to the site. Some osteoblasts become trapped within bone
matrix and differentiate to form osteocytes, which act as sensors of mechanical
strain in bone (Ralston, 1997).

precursor cells leading to the differentiation, migration, and fusion of mononuclear
cells to produce the large, multinucleated osteoclasts. These osteoclast cells attach to

10

the mineralized bone surface and initiate resorption by the secretion of hydrogen ions
and lysosomal enzymes, particularly cathepsins, which can degrade all the
components of bone matrix, including collagen, at low pH. Osteoclastic resorption
produces irregular, scalloped cavities called lacunae in the trabecular bone surface,
and called cylindrical Haversian canals in cortical bone. Once the osteoclasts have
completed their work of bone removal, there is a "reversal" phase during which
mononuclear cells, possibly of the macrophage lineage, are seen on the bone surface.
The events during this stage are not well understood, but they may involve further
degradation of collagen, the deposition of proteoglycans to form the so-called
cement line, and the release of growth factors to initiate the formation phase. During
the final "formation" phase of the remodeling cycle, the cavity created by resorption
can be completely filled in by successive layers of osteoblasts, deposition of
mineralizable matrix.
Most simply put, the challenges of understanding the complexities of skeletal
modeling and remodeling, are illustrated by the influences that osteoblasts have on
osteoclasts and vice versa (Marks et al., 1988; Mundy, 1994). The development and
differentiation of osteoblasts and osteoclasts, and consequently bone remodeling, is
controlled by growth factors and cytokines produced in the bone and bone marrow
microenvironment (Manolagas, 1998). Several systemic hormones, as well as
mechanical signals, also exert potent effects on osteoclast and osteoblast
development and differentiation (Raisz, 1993; Mosley, 2000).
The metabolic functions of the skeleton are served in large part by two major
calcium-regulating systemic hormones, parathyroid hormone (PTH) (Dempster et al.,
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1993; Hodsman et al., 1997) and 1,25-dihydroxy vitamin D3 (Li et al., 1998). PTH
regulates serum calcium concentration. It is a potent stimulator of bone resorption
and has biphasic effects on bone formation. There is an acute inhibition of collagen
synthesis with high concentrations of PTH, but prolonged intermittent administration
of this hormone produces increased bone formation, a property for which it is being
explored clinically as an anabolic agent (Dempster et al., 1993). 1,25-dihydroxy
vitamin D3 has its greatest effect on intestinal calcium and phosphate absorption, but
has direct effects on bone and other tissues (Li et al., 1998). It is probably critical for
the differentiation of osteoblasts and osteoclasts and can stimulate bone resorption
and formation under some experimental conditions (Norman, 1992). A third
hormone, calcitonin, which can inhibit bone resorption, may be important in skeletal
development but appears to play little role in physiologic calcium regulation in adult
humans (Whitfield et al., 2002; Doggrell, 2003; Stepan et al., 2003).
The most significant systemic hormone in regards to maintaining normal
bone turnover is estrogen (Pacifici, 1996; Pacifici, 1998). Estrogen deficiency leads
to an increase in bone remodeling in which resorption outstrips formation and bone
mass decreases. This can be observed not only in postmenopausal women, but also
in men with defects either in the estrogen receptor or in the synthesis of estrogen
from testosterone (Bilezikian et al., 1998). The mechanisms by which estrogen
regulates bone turnover are still not well understood, although studies in animals
suggest that estrogen acts by changing either the production or activity of local
factors that regulate osteoblast and osteoclast precursors (Lorenzo, 1992; Pacifici,
1998). Estrogen treatment produces a decrease in both formation and resorption of
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bone associated with decreased remodeling, but overall increases bone mass. This
increase may simply be a result of the filling in of the resorption space.
There is a concept that there must be local factors that also regulate bone
remodeling (McLeod et al., 1998). The identification of these local factors has
occurred only during the last 30 years. Among the first of the local factors to be
identified were cytokines. Originally these "osteoclast-activating factors", which
could be produced by inflammatory cells, particularly macrophages, were implicated
in the local bone loss associated with periodontal disease and inflammatory arthritis
(Lorenzo, 1992). At about the same time prostaglandins, particularly prostaglandin
E2, were shown to be potent stimulators of bone resorption that could also be
important in inflammatory bone loss (Kawaguchi et al., 1995).
A large number of cytokines and growth factors that can affect bone cell
functions have now been identified. The only factors capable of initiating
osteoblastogenesis from uncommitted progenitors are bone morphogenetic proteins
(BMPs) (Rosen et al., 1996; Sakou, 1998). BMPs have been long implicated in
skeletal development during embryonic life and fracture healing. More recently, it
has become apparent that BMPs, and in particular BMP-2 and BMP-4, also initiate
the commitment of mesenchymal precursors of the adult bone marrow to the
osteoblastic lineage (Abe et al., 2000). Other factors such as transforming growth
factor-β (TGF-β), platelet-derived growth factor (PDGF), insulin-like growth factors
(IGFs), and members of the fibroblast growth factor (FGF) family can all stimulate
osteoblast differentiation (Bonewald et al., Hakeda et al., 1996; Inui et al., 1998;
Mills et al., 1997). However, although TGF-β, PDGF, FGF, and IGFs are able to
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influence the replication and differentiation of committed osteoblast progenitors
toward the osteoblastic lineage, they cannot induce osteoblast differentiation from
uncommitted progenitor cells.
A large group of cytokines and colony-stimulating factors that are involved in
hematopoiesis also stimulate osteoclast development (Takahashi et al., 1991;
Fujikawa et al., 2001). This group includes several interleukins (IL-1, IL-3, IL-6, IL11), tumor necrosis factor-α (TNF-α), granulocyte macrophage-colony stimulating
factor (GM-CSF) and M-CSF. As opposed to the above listed cytokines that
stimulate osteoclast development, IL-10, IL-12 and IL-18 inhibit osteoclast
development (Horwood et al., 2001; Owens et al., 1996).
Recently, some of the proteins that are responsible for the interaction
between cells of the osteoblastic and osteoclastic lineage have been identified. These
proteins belong to the family of tumor necrosis factor receptors (Takahashi et al.,
1999; Yasuda et al., 1999; Khosla, 2001). Osteoblast precursors express a molecule
called TRANCE or RANKL, which can activate cells of the osteoclast lineage by
interacting with a receptor called RANK (Receptor Activator of NF-κB) (Takahashi
et al., 1999; Suda et al., 1999). A third molecule, osteoprotegerin (OPG), can be
produced by cells of the osteoblast lineage or by other cells in the marrow (Gori et
al., 2000). OPG acts as a decoy receptor for TRANCE, blocking its interaction with
RANK and inhibiting osteoclast formation (Aubin et al., 2000; Hofbauer et al., 2000;
Khosla, 2001). Recent studies have shown that knocking out the OPG gene in
rodents produces severe osteoporosis characterized by excessive bone resorption
(Kostenuik et al., 2001).
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Prostaglandin E2 (PGE2) was identified as a product of unstimulated and
complement-stimulated fetal rat long bones (Klein et al., 1970, Raisz et al., 1979).
Subsequently PGA2, PGI2, PGD2, PGE2, and PGF2α were found in bone cultures
(Klein et al., 1970). The discovery that PGI2 could be synthesized by the bone itself
was of substantial interest, as its short half-life would be of less consequence if it
was synthesized by cells on or immediately adjacent to the bone surface (Raisz et al.,
1979).
There are four known PGE2 receptors, EP1-4 and one prostaglandin F2α
receptor in bone (Suda et al., 1996; Nemoto et al., 1995). Little is known about
prostaglandin receptor functioning in bone cells, but there are indications that PGE2
stimulates osteoblastic differentiation in bone marrow cultures by activating the EP4
receptor, an effect that may involve recruitment of uncommitted osteogenic
precursors (Weinreb et al., 1999). In addition, a role of EP4 in PGE2-induced
osteoclast formation has been shown, suggesting a therapeutic potential of EP4
antagonists in some clinical conditions with accelerated bone resorption (Ono et al.,
1998; Suzawa et al., 2000). The EP1 subtype of PGE2 receptor plays a role in the
autoamplification of PGE2 (Funk et al., 1993; Suda et al., 1998; Suda et al. 2000).
The autoamplification of PGE2 production is considered to be important in
elongating the otherwise short-lived PGE2 action in certain physiological conditions
such as mechanical stress and fracture healing, as well as the pathological
inflammatory bone loss (Suda et al., 1998). A role for EP2 receptor has been
suggested in rapidly growing skeletal tissue (Nemoto et al., 1997).
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Prostaglandins are abundant in bone and are produced by cells of the
osteoblastic lineage (Raisz et al., 1993; Okada et al., 2003). They are complex
regulators of bone metabolism, being potent stimulators of bone resorption in organ
culture (Klein et al., 1970; Kawaguchi et al., 1995; Raisz, 1999), but inhibiting bone
resorption by isolated osteoclasts (Raisz, 1995; Kawaguchi et al., 1995). This
inhibitory effect was demonstrated in isolated osteoclasts but is difficult to exhibit
when osteoblasts are also present. PGE2 can mediate resorptive responses to
cytokines and growth factors in bone (Miyaura et al., 2000; Sakuma et al., 2000).
Although the effects of prostaglandins on bone resorption have been
studied to a much greater extent than those on bone formation, it seems likely that
their effects on bone formation will be of at least equal importance in regulation of
bone metabolism (Vrotsos et al., 2003). As with resorption, prostaglandins can also
stimulate and inhibit bone formation. High concentrations of prostaglandins can
inhibit collagen synthesis and reduce procollagen (I) mRNA levels in bone (Raisz et
al., 1993). The stimulatory effect can be observed in vitro either at low
concentrations or in the presence of cortisol and is probably indirect effect (Flanagan
et al., 1994; Gronowicz et al., 1994). Although the anabolic effect of prostaglandins
is indirect, it is a potent effect and may predominate in vivo (Jee et al., 1985; Jee et
al., 1987; Mori et al., 1990; Miller et al., 1994).
Prostaglandins are formed by most cells in our bodies and act as autocrine
and paracrine lipid mediators (i.e., signal at or immediately adjacent to their site of
synthesis) (Samuelsson, 1983; Six et al., 2000). They are not stored but are
synthesized de novo from membrane-released arachidonic acid when cells are
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activated by mechanical trauma or by specific cytokine, growth factor, and other
stimuli (e.g., collagen and adenosine diphosphate in platelets, bradykinin and
thrombin in endothelium). A host of enzymes regulate cellular levels of arachidonic
acid, keeping it esterified until mobilized by phospholipase A2 (PLA2). The control
of arachidonic acid release from membranes has undergone several paradigm shifts
in recent years with the continuing identification of new PLA2 members (Six et al.,
2000). Despite this, type IV cytosolic PLA2 (cPLA2) remains the key player for
eicosanoid production.
The levels of free arachidonic acid are normally very low since the liberated
fatty acid is rapidly metabolized (Samuelsson, 1987). Free arachidonic acid is a
substrate for two distinctively different enzymatic pathways, one leading to the
synthesis of PGs, the other to the hydroperoxy- and hydroxy-eicosatetraenoic acids
referred to as HPETEs and HETEs, respectively (Ford-Hutchinson, 1990). The two
pathways have in common the insertion of molecular oxygen into the fatty acid,
although PGs have an additional cyclopentane ring. Lipoxygenases (LOXs) are a
family of enzymes that catalyze the incorporation of molecular oxygen into
polyunsaturated fatty acids at specific positions to form active metabolites such as
HETEs. Three major LOXs have been characterized in mammals and designated as
5-, 12-, and 15-LOX, that produce 5(S)-, 12(S)-, 15(S)- hydroperoxides
(hydroxyperoxyiecosatetranoic acids, HPETEs) respectively, products that are
reduced to 5(S)-, 12(S)-, 15(S)- hydroxyeicosatetranoic acids (HETEs). The three
enzymes are known mainly from the blood cells in which they are robustly
expressed—the 5S-lipoxygenase in leukocytes, the 12S-lipoxygenase in platelets,

17

and the 15S-lipoxygenase in reticulocytes, macrophages and eosinophils (Brash et
al., 1997). Nevertheless selective expression is well documented in other tissues, for
example, both the 12S- and 15S-lipoxygenases are detected in skin (Nugteren et al.,
1987; Takahashi et al., 1993). 12-lipoxygenase generates from arachidonic acid the
bioactive lipid 12-hydroxyeicosatetranoic acid (12-HETE), which has been shown to
promote growth in chinese hamster ovary fibroblasts (Wen et al., 2000; Limor et al.,
2001), and the proliferation of pancreatic cancer cells (Brash et al., 1997). Studies
have suggested that the HETEs may activate osteoclasts and increase bone resorption
(Meghji et al., 1988). However, very little is still known about the exact roles the
HETEs play as regulators of bone remodeling.
Arachidonic acid released by the cytosolic isoform of the PLA2 (cPLA2) is
alternatively presented to prostaglandin H synthase (referred to colloquially as COX
for cyclooxygenase) pathway and the fatty acid is then metabolized into an
intermediate prostaglandin, PGH2. PGHS exists as two isoforms referred to as
PGHS-1 (COX-1) and PGHS-2 (COX-2) (Smith et al., 2000). In simple terms,
COX-1 is the enzyme responsible for basal, constitutive prostaglandin synthesis,
whereas COX-2 is important in various inflammatory and “induced” conditions
(Crofford, 1997; Vane et al., 1998). The constitutive COX-1 is mainly utilized in
immediate PGH2 biosynthesis, which occurs within several minutes after stimulation
with Ca2+ mobilizers, whereas the inducible COX-2 mediates delayed PGH2
biosynthesis, which lasts for several hours following proinflammatory stimuli.
COX-1 and COX-2 have been reported to exhibit subtle differences in AA
requirements, that is COX-2 is favored over COX-1 at low AA concentrations
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(Murakami et al., 1999), and differences in their subcellular localizations (Vane et
al., 1998). The COX enzymes are monotypically inserted into the ER and nuclear
membrane with the substrate-binding pocket precisely oriented to take up released
arachidonic acid. The crystal structures of COX-1 and COX-2 are remarkably
similar, with one notable amino acid difference that leads to a larger “side-pocket”
for substrate access in COX-2 (Smith et al., 2000).
Vane and coworkers found that the analgesic, antipyretic and antiinflammatory properties of acetylsalicylate (aspirin) were based on the inhibition of
prostaglandin synthesis (Vane, 1971). Vane showed that the acidic antiinflammatory analgesics decreased pro-inflammatory prostaglandin concentrations
by inhibiting cyclooxygenases. The cyclooxygenase activity of PGH synthase is the
target site of aspirin, ibuprofen and related nonsteroidal anti-inflammatory drugs
(NSAIDs) (Abramson et al., 1985; Higgs et al., 1987); most NSAIDs, including
aspirin, are competitive inhibitors of COX-1 (Kulmacz et al., 1985). NSAIDs, which
possess analgesic, anti-inflammatory and antipyretic properties, are a heterogeneous
group of substances without any uniform chemical properties, but nevertheless share
the same therapeutic and side effects. However, the selective blockade of the COX-2
isoform should lead to the inhibition of inflammation and pain without impeding the
COX-1-dependent prostaglandin production (Vane, 1994). This hypothesis led to an
intensive worldwide search for selective COX-2 inhibitors; since 1999 rofecoxib
(Vioxx®) and celecoxib (Celebrex®) have been available in the markets.
Downstream of the cyclooxygenases, the product PGH2 can be further
metabolized into various important eicosanoids, specifically PGE2, PGF2α, PGD2,
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PGI2, and thromboxane A2 (Smith, 1992) (Fig. 3.). The coupling of PGH2 synthesis
and metabolism by down stream enzymes is intricately coordinated in a cell-specific
fashion. Thromboxane synthase is found in platelets and macrophages, prostacyclin

Fig. 3. The three major pathways involved in arachidonic acid metabolism .
(a) The cyclooxygenase (COX) pathway results in the formation of prostaglandin
G2 (PGG2) from arachidonic acid by a cyclooxygenase reaction. In a subsequent
peroxidase reaction, PGG2 undergoes a two-electron reduction to PGH2. Both of
these reactions are catalysed by COX (prostaglandin synthase H). PGG2 serves as a
substrate for cell-specific isomerases and synthases, producing other eicosanoids.
(b) The lipoxygenase pathway forms hydroperoxyeicosatetraenoic acids (HPETEs)
and dihydroxyeicosatetraenoic acid (DEA) by lipoxygenase and subsequently
converts these to (1) hydroxyeicosatetraenoic acids (HETEs) by peroxidases, (2)
leukotrienes (e.g. LTC4) by hydrase and glutathione S-transferase (GST), and (3)
lipoxins by lipoxygenases. (c) The epoxygenase pathway forms epoxyeicosatrienoic
acid (EET) and dihydroxyacids by cytochrome p450 epoxygenase.
synthase is found in endothelial cells, both of which belong to the cytochrome P-450
family and are reportedly localized in the endoplasmic reticulum (ER) and
perinuclear membranes (Walsh, 1989; Ramos et al., 1995; Walsh, 2004). PGF2α
synthase in lung and liver are cytosolic proteins with high homology to the aldo20

reductase family (Suzuki et al., 1999; Suzuki-Yamamoto et al., 1999; SuzukiYamamoto et al., 2000). PGD2 synthases, which isomerize PGH2 to PGD2, occur in
two distinct forms, the haemopoietic PGDS (H-PGDS) is the key enzyme for
production of the D series of prostanoids in the immune system and mast cells
(Kanaoka et al., 1997), and the lipocalin-type PGDS (L-PGDS) that is abundantly
present in the central nervous system (Urade et al., 2000; Urade et al., 2002).
Two proteins that exhibit PGE2 synthase (PGES) activity have
been identified to date; they are the constitutive cytosolic PGES (cPGES), which is
identical to p23 (Nakatani et al., 2002), and the inducible, perinuclear membaranebound PGES (mPGES) (Murakami et al., 2002). Thus, PGE2 synthase activity is
present in both cytosolic and membrane fraction of cells, and the optimal catalytic
activity of each enzyme require glutathione (Tanioka et al., 2000; Nakatani et al.,
2002). Cytosolic PGES (cPGES), a GSH-requiring enzyme constitutively expressed
in a wide variety of cells, is functionally linked to COX-1, not COX-2, to promote
immediate PGE2 production (Tanioka et al., 2000). The expression of mPGES is
strongly induced by proinflammatory stimuli in vitro and at inflamed sites in vivo
and is down regulated by anti-inflammatory glucocorticoids (Stichtenoth et al.,
2001). mPGE2 synthase activity can also be induced by proinflammatory stimuli in
leukocytes (Fournier et al., 1997). Induction of mPGES-1 expression has also been
observed in various systems in which COX-2-derived PGE2 has been implicated to
play a critical role, such as inflammation, fever, pain, female reproduction, tissue
repair and cancer (Jakobsson et al., 1999; Murakami et al., 2000; Claveau et al.,
2003; Thoren et al., 2003; Kamei et al., 2003).
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The present studies were undertaken to examine the effects of TNF-α and
TGF-β, known mediators of osteoblast biology and bone remodeling, on PG and
HETE biosynthesis in the human osteoblast-like (hOB) cell model system. It is
possible that modulation of PGE2 synthesis by cytokines in various cells and tissues
may also have resulted, in part, from increased amounts of PGE2 synthases (cPGES
and mPGES), which are downstream of COX enzymes in the arachidonic acid
metabolic pathway for PGE2 production. To examine this possibility transcripts for
cPGES and mPGES were detected in hOB cells, by reverse-transcriptase polymerase
chain reaction using specific primers for human cPGES and mPGES.
Even though no cell culture model can exactly duplicate in vivo physiology,
non-transformed cells approximate normal biology to a greater extent than do
cancerous cells (Sporn et al., 1980). Therefore, in order to best mimic in vivo bone
biology, all of the experiments made use of cultured hOB cells. hOB cells are grown
from femoral bone explants and cultured in T-175 flasks, passaged twice, and then
used for experimentation. These hOB-like cells represent a fairly mature osteoblast
phenotype and respond appropriately to hormone and cytokine treatments (Robey
and Termine 1985; Keeting et al., 1991). The use of hOB cells obtained from human
bone explants avoids the problems of understanding and application of data acquired
from whole animal models, or from animal derived bone cells to human bone.
However, as with the other model systems there are limitations attendant with this
model system. For example, primary human cell cultures are derived from a
heterogeneous population, thus interstrain variations in characterstics and responses
of the cells can sometimes be large, thereby making analysis challenging.
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Furthermore, hOB cells have a limited life span and they grow slowly in culture
limiting the variables being tested on a single strain of cells. The difficulties
associated with studying such cells are counterbalanced with their suitability as a
model system representing authentic human osteoblasts.
The objectives of these studies were focused to: 1) describe the spectrum of
PGs and HETEs produced by hOB cells under basal and cytokine-stimulated
conditions and 2) to determine steady-state mRNA levels of cPGES or mPGES
which could lead to increased PGE2 production.
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MATERIALS AND METHODS

Experimental Subjects
Cancellous bone explants were obtained as surgical waste generated from the
femoral head during routine bone grafting procedures. The harvest of this waste
material following informed consent was approved by the West Virginia University
Internal Review Board. Patient records were evaluated, and explants were not taken
from patients with diagnosed osteoporosis or from patients presenting with endocrine
disorders known to affect bone. Bone explants used in the EIA experiments were
from 3 men aged 61 to 77 (median age of 64), and from 3 women aged 59 to 84
(median age of 80). Bone explants used in cPGES RT-PCR studies were from 3
women aged 23 to 85 (median age of 48) and 1 man aged 64. Bone explants used in
mPGES RT-PCR studies was from 2 men aged 75 and 64, 2 women aged 23 and 48.
Bone explants used in LOX RT-PCR studies were from 3 men aged 61 to 75 (median
age of 68).

hOB Cell Cultures
Cancellous bone explants were prepared and placed into culture according to
the method developed by Robey and Termine (1985), as previously described by
Cissel et al. (1996). The essential elements of this method include stripping the
explants in a 2 hour collagenase (1 mg/ml; Gibco, Grand Island, NY) digestion after
which the explants were placed in a calcium-free, phenol red-free mixture of
DMEM: Ham’s F12K (1:1) (Biofluids, Rockville, MD) supplemented to 8% heatinactivated fetal calf serum (FCS; Gibco). These culture methods yield nearly
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homogeneous cell cultures that display multiple aspects of the mature osteoblast
phenotype (Cissel et al. 1996, Borke et al., 1988). The hOB cell phenotype is stable
through at least 4 passages (Marie, 1994). All experiments described in this work
used hOB cells subcultured in 2nd or 3rd passage.

Reagents
Recombinant human tumor necrosis factor-α and recombinant human
transforming growth factor-β were purchased from R&D Systems (Minneapolis,
MN). IL-1β and IL-3 were purchased from BioRad. Stock solutions of each were
prepared according to the supplier’s instructions, and stored at –20o C for no more
than 4 months. PGE2, 6-keto PGF1α, PGF2α, PGD2, TXA2 and 15-HETEMonoclonal Enzyme Immunoassay (EIA) Kits were obtained from Cayman
Chemical Co. (Ann Arbor, MI). RT-PCR One-Step kits were obtained from
Invitrogen (Carlsbad, CA). Other chemicals and reagents used were of the highest
quality grade available. Oligonucleotide primers for human glyceraldehyde-3phosphate dehydrogenase (GAPdH), cPGES, mPGES and 15-Lipoxygenase type II
were purchased from Invitrogen. The oligonucleotide primers used were as follows:
mPGES, forward 5′-ATGCCTGCCCACAGCCTG-3′, and reverse 5′TCACAGGTGGCGGGCCGC-3′; for cPGES, forward 5′ATGCAGCCTGCTTCTGCA-3′, and reverse 5′-TTACTCCAGATCTGGCAT-3′
(Stichtenoth et al., 2001); for 15-lipoxygenase type II (Tang et al., 2002): forward 5’AACTCACCCCCACCACCATACACA-3’ and reverse 5’TTCCCGCCTCCATCTCCCAAAGT-3’, primers that amplify a 351 bp fragment
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and cover nucleotides 2234-2584 in the 3’-UTR (3’-untranslated region).
Amplification specificity of cPGES, mPGES, 15-lipoxygenase type II and GAPdH
sequences was assured by sequencing the subcloned gel purified PCR products from
our experiments (Univ. California-Davis Sequencing Laboratory).

hOB Cell Incubations
hOB cells were subcultured at 50,000 cells/well into 24-well plates (EIAs) or
at 150,000 cells/well into 12-well plates (RNA assays) in medium supplemented to 1
mM calcium and 10% (v/v) FCS (see flow chart below). In all experiments the
calcium concentration of the media was thereafter maintained at 1 mM.

48 hrs
48 hrs
24hrs(conditioned media) or 6-8hrs(RNA)
Subculture ⎯→ Media change ⎯→ Media change ⎯→ Harvest Conditioned Media
(10% FCS)
(1% FCS)
(10% FCS ± Cytokines)

Forty-eight hours after subculturing, media were replaced and the FCS was reduced
to 1% for an additional 48 hours. Media were changed and the experimental
manipulations were initiated by the addition of 20 nM TNF-α, 40 pM TGF-β, TNFα plus TGF-β, TNF-α and TGF-β plus ibuprofen, or vehicle for 24-hours when
harvesting conditioned media for EIA studies, or for 6-8 hours when harvesting total
RNA. For 15-lipoxygenase type II RT-PCR studies, hOB cells were exposed to
growth factors and cytokines at final concentrations as follows: TGF-β at 40 pM;
TNF-α at 400 pM alone, and in combination with TGF-β; IL-1β and IL-3 at 300 pM.
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These concentrations of TGF-β, TNF-α, and IL-1β elicit their maximum effects on
hOB cell PGE2 production (Xu et al., 1997). The concentration of IL-3 was based on
the literature (Li et al., 1992).

Immunochemical Assays for PGs
hOB cells were subcultured in 24-well plates at a density of 50,000
cells/well. After the 48 hour attachment, the cells were placed in 1% FCS for an
additional 48 hours. Following the replacement of 1% with 10% FCS, cytokines, or
vehicle, were added to the media as described. After treatment, the conditioned
media were collected and were stored at –80oC until assayed. PGE2, 6-keto PGF1α,
PGF2α, PGD2, TXA2 and 15-HETE were measured in hOB cell conditioned media
using specific EIA kits according to the supplier’s instructions (Cayman Chemical).
Each sample was assayed at least two dilutions and performed in duplicate. The
detection limit for different prostaglandins were PGE2 15 pg/ml, 6-keto PGF1α 11
pg/ml, PGF2α 9 pg/ml, PGD2 3.1pg/ml, TXA2 11pg/ml and 15-HETE 170 pg/ml at
80% B/B0. Briefly, the assay is based upon the competition between PG or 15-HETE
in the sample or standards and the respective PG or 15-HETE acetylcholine-esterase
conjugate (tracer) for a limited amount of specific monoclonal antibody.
The limits of detection at (80%B/B0) for different kits were as follows:
Prostaglandin E2- 15 pg/ml, 6 keto-Prostaglandin F1α -11 pg/ml, Prostaglandin F2α 9 pg/ml, Prostaglandin D2 - 3.1 pg/ml, Thromboxane B2 - 11pg/ml and 15-HETE 170 pg/ml. The intra- and interassay coefficient of variations (CVs) for: PGE2 were
4.8% and 13.2% respectively, 6-ketoPGF1 were 5.2% and 12.0% respectively,
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PGF2 were 4.4% and 12.9% respectively, PGD2 were 5.2% and 2.9% respectively,
15-HETE were 5.7% and 8.7% respectively.

Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
RT-PCR analysis was preferred over Northern blotting to assess specific
mRNA levels due to cell culture limitations and the high costs associated with TNF
treatments. hOB cells were subcultured at a density of 150,000 cells/well in 12-well
plates in 10% FCS medium. After 48 hours, media were changed to 1% FCS for 48
hours. Following the replacement of 1% with 10% FCS, the cytokines were added to
the media 6-8 hours before harvesting the cells for RNA preparations. Total RNA
was isolated using the TRIZOL Reagent (Invitrogen) and DNAase treated. RNA
yields were estimated by absorbance at 260 nm, and the reverse transcriptions and
amplifications were performed starting with 50 ng of total RNA per sample, using
the RT-PCR One-Step kit according to the manufacturer’s recommendations.
Thirty-five cycles of amplifications were performed for cPGES at 50°C, 32 cycles for
mPGES at 65°C, 35 cycles for 15-lipoxygenase type II at 65°C and 25 cycles for
GAPdH at 55°C, leaving each product in its linear range. Hybridization intensities in
these experiments were determined using the BioRad Fluor-STM MultiImager gel
documentation system with their software. All data are presented as “ Fold-basal” in
which the band intensity of the treated specimens was compared with that of its
respective control after correcting for concurrently amplified human GAPdH levels
in the control and treated specimens.

28

Statistical Analyses
Data were analyzed using the SAS-JMP statistical package. Data for PGs
and HETE production as measured by EIA are presented as “Fold-basal” to represent
the response of the cells to treatment compared with basal production. Because hOB
cells are derived from the heterogeneous human population, variation between cell
strains makes a normalization method (i.e.,“Fold basal”) desirable to assist in
permitting meaningful comparisons. Data are presented as the mean ± SEM of N
experiments using different hOB cell strains. Intra-assay coefficient of variation
(CV) was calculated by comparing variation between replicate samples using the
formula CV=(Std. Dev./Mean)*100. Inter-assay coefficient of variation (CV) was
calculated by comparing variation between samples obtained from similar
experiments performed on different days using the similar kit using the formula
CV=(Std. Dev./Mean)*100. In the RT-PCR studies, individual band intensities were
first normalized to the samples respective GAPdH band intensity. These values were
then expressed as a percentage of control sample value, and treatment effects were
analyzed.
The data were analyzed by the paired t-test (e.g. cytokine effects on PGE2
production by hOB cells) using the SAS-JMP statistical package. Statistical
significance was examined by these tests using p< 0.05 as the significance level.
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RESULTS

Effects of cytokines on biosynthesis of arachidonic acid metabolites
Previously published TLC analyses (Fig. 4; with permission from Dr. Philip
E. Keeting) and EIA studies from this laboratory guided investigations into EIAs to

AA
15-HETE
12-HETE
13,14-PGE2

PGE2
PGF2α
6-k-PGF1α

Origin
Control

TNF

TGFβ

TGFβ
+TNF

Figure 4. hOB cells were preradiolabeled with 1-[14C]arachidonic acid for 24
hours, and stimulated with or without cytokines, as indicated. Twenty-four-hour
cell-conditioned media were collected, extracted, products separated by thin layer
chromatography, and the TLC plates used to expose x-ray film. Metabolites were
identified by the comigration of authentic standards.
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further define and characterize the role of cytokines in the modulation of PG and
HETE production in hOB cell cultures. These TLC studies indicated that the
application of TGFβ or TNFα alone, and in combination, elevated 1-[14C]-PGE2
formation several fold, and produced modest increases of perhaps two-five fold in
the levels of 1-[14C]-6-keto-PGF1α in hOB cells. In some of these studies a band
corresponding to PGF2α was observed. Bands corresponding to the migration of
authentic 12-HETE and 15-HETE were also seen in some experiments. The 15HETE band was increased in cytokine stimulated specimens, and appeared to be
decreased when aspirin or ibuprofen, both inhibitors of COX, was included. 12HETE formation did not appear to vary by treatment. Production of other PG
metabolites, such as TxB2 or 5-HETE, by the hOB cells was not detected using the
TLC procedure.
In the present studies, conditioned media harvested from hOB cell cultures
were assayed by prostalandin specific EIAs to determine quantitatively the effects of
cytokines on PGE2, 6-keto-PGF1α, PGF2α, PGD2, thromboxane (TXB2) and on 15HETE biosynthesis. The main product of PGH2 in the conditioned media was found
to be PGE2, with lesser amounts of 6-keto-PGF1α, PGF2α, and PGD2 detected (Figure
5 and Table 2). TXB2 was not detected in control samples, or in samples stimulated
with cytokines. 15-HETE was produced by the hOB cells, and was sensitive to
modulation by the cytokines and ibuprofen.
EIA analysis indicated that PGE2 was the predominant PG metabolite
released by unstimulated hOB cells and its synthesis was increased more than other
PGs in cells treated with TGFβ and TNFα, both separately and in combination,
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Increases in PGs and 15-HETE when hOB cells treated by cytokines

45
40
35

Fold-Basal

30
PGE2

25

6-k-PGF1a
PGF2a

20

PGD2
15-HETE

15
10
5
0
-5

TGF-b

TNF-a

TGFb-+TNF-a

TGF-a+TNF-b+ ibu

Fig. 5. Summary of PGs and 15-HETE stimulation by TGF-β and TNF-α
hOB cells were treated with 20 nM TNF-α and 40 pM TGF-β in combination or
separately. In some specimens, fifty µM of ibuprofen was used in combination with
20 nM TNF-α and 40 pM TGF-β for 24 hrs in 10% FBS supplemented medium. PGs
and HETEs were assayed by EIA (N=5).
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agreeing with previous observations (Xu et al., 1997) (Table. 2). Basal production of
PGE2 in control samples was measured at 9.5 ± 5.1 ng/ml (N=5). TNFα alone and in
combination with TGFβ over a 24 hr incubation significantly increased PGE2 levels
(N=5, p<0.05). In combination the cytokines increased PGE2 formation to 32.3 ± 9
fold-basal (N=5, p<0.05), a response dramatically different from the increase elicited
by TGFβ alone (6.4 ± 1.8 fold; p<0.05 vs. control), but not significantly different
from the response to TNFα (18.5 ± 6.1 fold; p<0.05 vs. control). Samples treated
with TGFβ and TNFα in the presence of ibuprofen (2.8 ± 0.7 fold; p<0.05 vs.
control; p<0.05 vs. TGFβ, TNFα or Both) exhibited an attenuated response. A
significant difference in PGE2 formation was found between TNFα treated samples
(18.5 ± 6.1 fold-basal) vs. TGFβ plus TNFα plus ibuprofen (2.8 ± 0.7 fold basal)
(Table 2).
6-keto-PGF1α was the second most predominant PG found in hOB cells,
although the amounts found did not approach the amount of PGE2 under either basal
(0.5 ± 0.1 ng/ml vs. 9.5 ng/ml) or maximal stimulated conditions (4.7 ± 0.2 ng/ml vs.
306.9 ± 45 ng/ml). The cytokine dependent increase in 6-keto-PGF1α formation in
hOB cells was a significant 9.4 ± 1.6 fold-basal in specimens treated with TGFβ and
TNFα in combination (Table 3). Ibuprofen inclusion blocked the cytokine
stimulated increase (0.1 ± 0.0 fold-basal). TNFα increased 6-keto-PGF1α formation
significantly to 7.0 ± 2.0 fold-basal.
Basal production of PGF2α in control samples was 0.2 ± 0.0 ng/ml (N=5)
(Table 4). PGF2α production was stimulated by cytokines individually, and in
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Table 2. Effect of cytokines and Ibuprofen on PGE2 synthesis by hOB cells

Treatment

Fold Basal
1.0 ± 0.0
6.4 ± 1.8
18.5 ± 6.1a
32.3 ± 9.0a
2.8 ± 0.7b,c

Control
TGF-β
TNF-α
TNF-α+TGF-β
TNF-α+TGF-β+ ibuprofen

hOB cells were treated with 20 nM TNF-α and 40 pM TGF-β in combination or
separately. Fifty µM of ibuprofen was used in combination with 20 nM TNF-α and
40 pM TGF-β for 24 hrs in 10% FBS supplemented medium. PGE2 was assayed by
EIA (N=5). The data are presented as the mean ± SEM of five individual cell
strains. The basal production of PGE2 was 9.5 ± 5.1 ng/ml.
a

, p<0.05, by comparison with control (by student’s t-test).
, p<0.05, by comparison with TNF-α (by student’s t-test).
c
, p<0.05, by comparison with TNF-α+TGF-β (by student’s t-test).
b
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Table 3. Effect of cytokines and Ibuprofen on 6-keto-PGF1α synthesis by hOB cells

Treatment

Fold Basal
1.0 ± 0.0
4.7 ± 1.6
7.0 ± 2.0a
9.4 ± 1.6a
0.1 ± 0.0b,c

Control
TGF-β
TNF-α
TNF-α+TGF-β
TNF-α+TGF-β+ ibuprofen

hOB cells were treated with 20 nM TNF-α and 40 pM TGF-β in combination or
separately. Fifty µM of ibuprofen was used in combination with 20 nM TNF-α and
40 pM TGF-β for 24 hrs in 10% FBS supplemented medium. 6-keto-PGF1α was
assayed by EIA (N=5). The data are presented as the mean ± SEM of five individual
cell strains. The basal production of 6-keto-PGF1α was 0.5 ± 0.1 ng/ml.
a

, p<0.05, by comparison with control (by Tukey-Kramer’s method).
, p<0.05, by comparison with TNF-α (by Tukey-Kramer’s method).
c
, p<0.05, by comparison with TNF-α+TGF-β (by Tukey-Kramer’s method).
b

35

Table 4. Effect of cytokines and Ibuprofen on PGF2α synthesis by hOB cells

Treatment

Fold Basal

Control
TGF-β
TNF-α
TNF-α+TGF-β
TNF-α+TGF-β+ ibuprofen

1.0 ± 0.0
8.1 ± 1.7b
11.8 ± 4.5a,b
25.4 ± 4.0a
0.3 ± 0.1b

hOB cells were treated with 20 nM TNF-α and 40 pM TGF-β in combination or
separately. Fifty µM of ibuprofen was used in combination with 20 nM TNF-α and
40 pM TGF-β for 24 hrs in 10% FBS supplemented medium. PGF2α was assayed by
EIA (N=5). The data are presented as the mean ± SEM of five individual cell
strains. The basal production of PGF2α was 0.2 ± 0.0 ng/ml.
a

, p<0.05, by comparision with control (by Dunnett’s method)
, p<0.05, by comparision with TNF-α and TGF-β in combination (by student’s ttest).

b
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combination, reaching a maximum increase to 25.4 ± 4.0 fold-basal (N=5) with the
combination treatment of TGFβ plus TNFα. TNFα individually elevated PGF2α
production significantly to 11.8 ± 4.5 fold-basal.
There was also a significant difference in the stimulated PGF2α synthesis
between the combined application of TGFβ and TNFα (25.4 ± 4.0 fold-basal) versus
treatment of TGFβ alone (8.1 ± 1.7 fold-basal) or TNFα alone (11.8 ± 4.5 foldbasal). Ibuprofen treatment blocked the cytokine stimulated increase in PGF2α
production (0.3 ± 0.1 fold-basal).
PGD2 production by hOB cells had not been reported previously. In the
present studies, the level of PGD2 in unstimulated samples was measured at 0.02 ±
0.01 ng/ml (N=5). The capacity of the cytokines in combination and individually to
modulate PGD2 formation was examined, and TGFβ and TNFα in combination
stimulated PGD2 formation significantly (18.7 ± 2.9 fold-basal; p<0.05). This
increase in PGD2 formation with TGFβ plus TNFα in combination was significantly
different from samples treated with TGFβ alone (4.5 ± 0.9 fold-basal), TNFα alone
(7.1 ± 1.9 fold-basal), and TGFβ and TNFα plus ibuprofen (0.6 ± 0.1 fold-basal).
TNFα alone elevated PGD2 formation significantly over basal PGD2 formation (7.1
± 1.9 fold-basal) (Table 5).
The basal level of 15-HETE in hOB cell samples was 0.5 ± 0.1 ng/ml (N=5)
(Table 6). TGFβ and TNFα applied in combination elevated 15-HETE biosynthesis
significantly (5.3 ± 0.8 fold-basal). There was a significant difference in the 15HETE levels between application of TGFβ and TNFα in combination compared to
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Table 5. Effect of cytokines and Ibuprofen on PGD2 synthesis by hOB cells

Treatment

Fold Basal

Control
TGF-β
TNF-α
TNF-α+TGF-β
TNF-α+TGF-β+ ibuprofen

1.0 ± 0.0
4.5 ± 0.9c
7.1 ± 1.9a,c
18.7 ± 2.9a
0.6 ± 0.1b,c

hOB cells were treated with 20 nM TNF-α and 40 pM TGF-β in combination or
separately. Fifty µM of ibuprofen was used in combination with 20 nM TNF-α and
40 pM TGF-β for 24 hrs in 10% FBS supplemented medium. PGD2 was assayed by
EIA (N=4). The data are presented as the mean ± SEM of four individual cell
strains. The basal level of PGD2 was 0.02 ± 0.05 ng/ml.
a

, p<0.05, by comparision with control (by student’s t-test).
, p<0.05, by comparision with TNF-α (by student’s t-test).
c
, p<0.05, by comparision with TNF-α+TGF-β (by student’s t-test).
b
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Table 6. Effect of cytokines and Ibuprofen on 15-HETE synthesis by hOB cells

Treatment

Fold Basal
1.0 ± 0.0
1.9 ± 0.3c
2.9 ± 0.9a,c
5.3 ± 0.8a
0.8 ± 0.1b,c

Control
TGF-β
TNF-α
TNF-α+TGF-β
TNF-α+TGF-β+ ibuprofen

hOB cells were treated with 20 nM TNF-α and 40 pM TGF-β in combination or
separately. Fifty µM of ibuprofen was used in combination with 20 nM TNF-α and
40 pM TGF-β for 24 hrs in 10% FBS supplemented medium. 15-HETE was assayed
by EIA (N=5). The data are presented as the mean ± SEM of five individual cell
strains. The basal level of 15-HETE was 0.5 ± 0.1 ng/ml.
a

, p<0.05, by comparision with control (by student’s t-test).
, p<0.05, by comparision with TNF-α (by student’s t-test).
c
, p<0.05, by comparision with TNF-α and TGF-β (by student’s t-test).
b
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treatment with TGFβ alone (1.9 ± 0.3 fold-basal) or with TNFα alone (2.9 ± 0.9 fold
basal). Ibuprofen application inhibited the cytokine stimulated increase in 15-HETE
(0.8 ± 0.1 fold-basal) (Table 6).
EIAs were also performed to measure TXB2 in unstimulated hOB cells, and
cells treated with cytokines separately and in combination. TXB2 was undetectable.
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Effect of cytokines on Prostaglandin E2 synthases
The possibility that the up-regulation of PGE2 synthesis elicited by cytokines
might have resulted from an increased level of the terminal PGE2 synthases (cPGES
and mPGES) which act downstream of COX enzymes in the arachidonic acid
metabolic cascade for PGE2 production was tested. Transcripts for cPGES and
mPGES was assessed by the reverse-transcriptase polymerase chain reaction using
specific primers for human cPGES and mPGES (Stichtenoth et al., 2001). cPGES
and mPGES cDNAs had 482 and 458 nucleotides respectively.
cPGES mRNA in hOB cells was detected in unstimulated control samples
(Fig. 5.). Upon dual cytokine stimulation, an up-regulation of cPGES mRNA was
observed. A non-significant change in the cPGES mRNA level was observed in
specimens stimulated singly with TGFβ (2.5 ± 0.4 fold basal, N=4), or with TNFα
(4.6 ± 1.4 fold basal, N=4). The conjoint treatment of TGFβ and TNFα significantly
increased the steady state level of cPGES mRNA (5.3 ± 1.3 fold-basal, N=4,
p<0.05).
The mRNA levels of mPGES, was assessed utilizing RT-PCR technique, and
the outcome for mPGES mRNA assays was generally similar to that of cPGES in
response to the proinflammatory cytokines. mPGES mRNA expression was assayed
in hOB cells following treatment with TGFβ (2.7 ± 0.7 fold-basal, N=4), or with
TNFα versus control samples (4.5 ± 1.6 fold-basal, N=4). Neither response reached
significance in these studies. TGFβ plus TNFα in combination significantly
increased the mPGES mRNA level (5.3 ± 1.7 fold basal, N=4, p<0.05) (Fig. 6.).
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Figure 6. RT-PCR based experiments tested whether the mRNA level of cPGES was
sensitive to TGFβ and/or TNFα treatment. The top panel illustrates the results of an
experiment using hOB cells from a 23 year old woman. Specimens were treated with
or without TGFβ, TNFα, or TGFβ plus TNFα for 6-8 hours. The bar graphs
represent the relative levels of cPGES mRNA after normalizing to GAPdH levels in
the pooled samples (N=4).
*, p<0.05, by comparision with control samples (Student’s t-test).
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Figure 7. RT-PCR based experiments tested whether the mRNA level of mPGES was
sensitive to TGFβ and/or TNFα treatment. The top panel illustrates the results of an
experiment using hOB cells from a 75 year old man. Specimens were treated with or
without TGFβ, TNFα, or TGFβ and TNFα for 6-8 hours. The bar graphs represents
the relative levels of mPGES mRNA after correcting for GAPdH levels in the various
samples (N=4).

*, p<0.05, by comparision with control samples (Student’s t-test).
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Effect of cytokines on 15-lipoxygenase type-II
The steady-state level of 15-Lipoxygenase type-II mRNA in the hOB cells
was determined in control samples and specimens treated with TGFβ and/or TNFα,
IL-3 and IL-1β (Fig. 7a,b). A significant increase in 15-LOX type-II mRNA level
was evident in specimens treated with TNFα alone (47.9 ± 22 fold-basal). The
specimens treated with following treatments elicited a non-significant increase in 15LOX type-II mRNA level, with TGFβ alone (2.7 ± 1.1 fold-basal); TGFβ plus TNFα
(11.6 ± 4.6 fold-basal); IL-3 (5.7 ± 2.9 basal) and with IL-1β (14.2 ± 9.3 fold-basal).
11

2

33 4

45

65

6

≈GAPdH

≈15-LOX-II

1=Control; 2=TGFβ; 3=TNFα;
4=TGF /TNFα; 5=IL-3; 6=IL-1β

Figure 8a. RT-PCR based experiments tested whether the mRNA level of 15lipoxygenase type-II was sensitive to TGFβ and/or TNFα, IL-3 and IL-1β treatments.
Specimens were treated with or without TGFβ, TNFα, or TGFβ plus TNFα, IL-3, or
IL-1β for 6-8 hours. The top panel illustrates the results of an experiment using hOB
cells from a 75 year old man.
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Figure 8b. RT-PCR based experiments tested whether the mRNA level of 15lipoxygenase type-2 was sensitive to TGFβ and/or TNFα, IL-3 and IL-1β treatments.
*, significantly different from control and other treatments at p<0.05, N=3 (by
student’s t-test).
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DISCUSSION

Our enzyme-immunoassay data show that the predominant prostaglandin
metabolite found in the conditioned media of unstimulated and cytokine-challenged
hOB cells was PGE2. Basal PGE2 production may have been primarily the result of
a constitutive COX-1 activity (Smith et al., 1996). The treatment with TGFβ or
TNFα, alone and in combination, increased PGE2 biosynthesis; the maximum
response was a 32-fold increase following stimulation by the conjoint application of
TGFβ plus TNFα, probably due to increased COX-2 expression and activity (Smith
et al., 1996; Xu et al., 1997). Researchers have demonstrated the involvement of
COX-2 induction and subsequent increased PGE2 production by cytokines, such as
IL-1β and TNFα, in the bone resorptive disorders of postmenopausal osteoporosis
and rheumatoid arthritis joint destruction (Kawaguchi et al., 1995).
TGFβ and TNFα are products of various types of cells including hOB cells,
and hOB cells are responsive to treatment with these cytokines when added
exogenously (Raisz, 1993; Kuroki et al., 1994). Thus, TGFβ and TNFα serve as
autocrine/paracrine regulators in osteoblast cells. Supporting this statement is the
observation by Dodds et al. (1994) of TGFβ and TNFα mRNA expression in
osteoblasts localized to remodeling sites in human bone sections. Cytokines regulate
prostaglandin production in a tissue specific manner, and TGFβ has been reported to
promote, and to oppose, augmented PG production with specificity to different
tissues (Goppelt-Struebe, 1995). TNFα appears to act solely to increase PG
biosynthesis (Crofford, 1997).
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The results of the present studies are consistent with the results and
conclusions drawn from an earlier published report from this laboratory (Xu et al.,
1997). An overall 32-fold potentiation of PGE2 biosynthesis by TGFβ and TNFα
treatment was recorded in the present studies; a 22-fold increase under these
conditions was previously reported, and described as synergistic (Xu et al., 1997).
Opposing/or synergistic interactions of TGFβ and TNFα are not restricted to hOB
cells but are also seen in studies of rat mesangial cells, human airway epithelial cells,
and fetal rat calvarial osteoblasts. In rat mesangial cells, TGFβ and TNFα in
combination synergistically up-regulate fibronectin expression (Pawluczyk et al.,
1998). Disparate interaction effects for TGFβ and TNFα mediation of GM-CSF and
IL-8 expression in human airway epithelial cells have been reported (Jagels et al.,
2000). In fetal rat calvarial osteoblasts a TNFα-stimulated increase in secretory
PLA2 release was opposed by TGFβ, as was a TNFα- dependent increase in COX-2
mRNA expression (Pruzanski et al., 1998).
In our studies the inhibitory effect of ibuprofen on PGE2 production in hOB
cells was obvious. The non-steroidal antinflammatory drugs (NSAIDs, e.g.,
ibuprofen) inhibit prostaglandin biosynthesis by inhibiting the cyclooxygenase
enzymes. The present results were consistent with the earlier published report by Xu
et al. (1997).
It should be noted that the present study is limited to in vitro experiments. In
fact, PGE2, particularly in the bone cells, has a very important role since
it is known to have potent effects not only on bone resorption (Kawaguchi et al.,
1995; Raisz 1999; Miyaura et al., 2000; Sakuma et al., 2000), but also on bone
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formation in vivo (Jee et al., 1985; Jee et al., 1987; Mori et al., 1990; Miller et al.,
1994). The recognized resorption effect of prostaglandins on bone has been
repeatedly confirmed since it was first reported by Klein and Raisz (1970).
Numerous reports indicate that PGE2 stimulates bone resorption in mouse and rat
bone cultures (Farndale et al., 1988), participates in the development of the bone
resorbing osteoclasts from mononuclear cells, and can directly regulate osteoclast
activity (Raisz et al., 1975; Roodman, 1996). The osteogenic effects are mainly seen
when a substantial amount of exogenous PGE2 was applied locally or systemically
(Raisz et al., 1993; Kawaguchi et al., 1995), and PGE2 can prevent ovariectomyinduced cancellous bone-loss in rats (Jee et al., 1990; Mori et al., 1992; Welch et al.,
1993). Thus, the regulatory actions of PGE2 in bone are diverse, and include the
mediation of cyclic nucleotide accumulation (Partridge et al., 1981; Klein-Nulend et
al., 1990; Yu et al., 1976; Atkins et al., 1977), cell proliferation (Hakeda et al., 1987;
Raisz et al., 1990) are among its other recognized actions (Raisz et al., 1983; Raisz,
1988; Shen et al., 1986; Evans et al., 1990).
Prostaglandin production is a multi-step process (Smith et al., 1996).
Esterified arachidonic acid is released from membrane glycerophospholipids by
activated phospholipases. The activity of the downstream cyclooxygenase enzyme is
rate-limited by liberated arachidonic acid availability (Smith et al., 1996), which is
supplied through phospholipase A2 hydrolysis of membrane glycerophospholipids.
This available free arachidonic acid can then be used as a substrate by the COX
enzymes to form the unstable transitional cyclic endoperoxide PGH2. Further,
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downstream of the cyclooxygenases, terminal conversion of PGH2 to PGE2 takes
place, which may be catalyzed by either of two isoforms of PGE2 synthase (PGES).
The regulatory mechanisms of PGE2 production may involve multiple
regulation mechanisms. One mechanism regulating cytokine-stimulated PGE2
production could be effects on release of arachidonic acid from membrane
glycerophospholipids by the activity of cytosolic PLA2 (cPLA2). This enzyme is
critical for PG biosynthesis (Fujishima et al., 1999) and provides the necessary
substrate for the newly expressed COX-2 protein after cytokine stimulation. It has
been reported that TNFα mediates PG biosynthesis by activating cPLA2 and by
increasing the rate of phospholipase A2 synthesis in bone cultures (Yanaga et al.,
1992; Kawaguchi et al., 1996), an effect that may be duplicated in hOB cells
(Secreto et al., submitted to Prostaglandins & Other Lipid Mediators). Proinflammatory cytokines have also been reported to stimulate PLA2 activity and/or
expression in mesangial and epithelial cells (Pfeilschifter et al., 1989; Newton et al.,
1997).
The second PGE2 production regulatory site is the inducible cyclooxygenase2 gene. Previous work reported from this laboratory (Xu et al., 1997) demonstrated
that TGFβ and TNFα can independently elevate the levels of COX-2 mRNA
resulting in increased formation of PGE2. When both cytokines were added to
specimens concurrently, the independent stimulation of hOB cell COX-2 mRNA
levels, protein levels, and prostaglandin biosynthesis was further elevated (Xu et al.,
1997; Secreto et al., 2003). Some researchers have reported that TGFβ can stimulate
COX-2 mRNA expression in MC3T3-E1 cells (Pilbeam et al., 1997). Our result
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shows that COX-2 activity is regulated by TGFβ and TNFα in hOB cells, as is
evident by the stimulation of PGE2 production by these cytokine treatments. This
conclusion is supported by the inhibitory effects of the NSAID ibuprofen on PGE2
formation.
The identification of an inducible PGE synthase in hOB cells opens up new
avenues for studying the regulation of PGE2 biosynthesis by pro-inflammatory
cytokines. The third regulatory site for PGE2 production is the membrane-associated
PGES (mPGES), which was originally designated microsomal glutathione Stransferase 1-like 1 (MGST1-L1). This is an inducible enzyme, which is
coordinately induced with COX-2 and is functionally coupled with COX-2
(Jakobsson et al., 1999; Murakami et al., 2002). mPGES expression is induced by
proinflammatory cytokines in various cells and tissues, now including hOB cells as
indicated by the results of the present studies, and is down-regulated by
dexamethasone, accompanied by changes in COX-2 expression and subsequent
PGE2 production (Murakami et al., 2000).
The present study indicates the presence of the mRNAs for the microsomal
and the cytosolic PGES enzymes in hOB cells. mPGES mRNA message in hOB
cells appeared to increase modestly with TGFβ or TNFα treatment. The concurrent
treatment of hOB cells with both cytokines increased mPGES mRNA levels by 5fold, to a level that was significantly different from that observed in unstimulated
control hOB cells. These results are consistent with the accumulated evidence from
various studies which show that mPGES is an inducible enzyme, the expression of
which is markedly increased, in a manner similar to COX-2, in various cells and
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tissues following several usually proinflammatory stimuli (Jakobsson et al., 1999;
Soler et al., 2000; Stichtenoth et al., 2001; Murakami et al., 2002; Yamagata et al.,
2001; Han et al., 2002). Proinflammatory cytokines are reported to induce mPGES
mRNA levels in synovial cells (Stichtenoth et al., 2001), thus, mPGES might also be
involved in the pathophysiology of the rheumatoid arthritis joint destruction. The
nearby osteoblasts may then contribute to the PGE2 levels found in synovial fluids,
perhaps, thereby exacerbating the localized inflammation. mPGES is reported to be
expressed and up-regulated transcriptionally by proinflammatory cytokines in the
macrophage cell line RAW 264.7 (Naraba et al., 2002). Lately, membraneassociated PGE2 synthase (mPGES) has been identified in the mouse coculture
system of osteoblasts and bone marrow cells (Saegusa et al., 2003). In cultured
mouse primary osteoblasts, both mPGES and cyclooxygenase-2 were induced by the
bone resorptive cytokines interleukin-1, tumor necrosis factor-α, and fibroblast
growth factor-2 (Saegusa et al., 2003). Induction of mPGES was also seen in mouse
long bone and bone marrow in vivo by intraperitoneal injection of
lipopolysaccharide. An antisense oligonucleotide blocking mPGES expression
inhibited not only PGE2 production, but also osteoclastogenesis and bone resorption
stimulated by the cytokines (Saegusa et al., 2003). Unlike NSAIDs, which inhibit
COX activity and suppress not only PGE2 but also production of other possibly
essential prostanoids, an inhibitor of this PGE2 specific enzyme (PGES) could
provide a highly selective treatment with low side effects on other aspects of tissue
homeostasis.
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cPGES mRNA expression also increased in a similar fashion that of mPGES
in hOB cells. These findings are in contrast with earlier reports that found cytosolic
PGES (cPGES) was expressed ubiquitously and constitutively, and that mRNA
levels were unaltered by proinflammatory stimuli in a wide variety of cells and
tissues, where cPGES promotes COX-1 mediated immediate PGE2 production
(Tanioka et al., 2000). cPGES is expressed constitutively both in the mouse
coculture system of osteoblasts and bone marrow cells, and mouse long bone in vivo
without being affected by bone resorptive stimuli (Saegusa et al., 2003). This COX1 and cPGES coupling is assumed to contribute to the basal production of PGE2,
which plays a role in the maintenance of tissue homeostasis.
Our EIA data suggests cytokine treatments individually had little effect on 6keto-PGF1α biosynthesis, but that the conjoint application of TGFβ and TNFα
elevated 6-keto-PGF1α by five-fold over basal production in unstimulated cells.
Ibuprofen, when administered along with TGFβ and TNFα, blocked the formation of
this prostanoid. These results are in line with the earlier reported RIA and TLC data
by this laboratory (Xu et al., 1997). 6-keto-PGF1α is the second most abundant PG
produced in bone (Raisz, 1995; Kawaguchi et al., 1995). PGI2, the precursor of 6keto-PGF1α, reportedly inhibits osteoclastic bone resorption, and completely
abolishes the normally intense cytoplasmic motility of isolated osteoclasts
(Chambers et al., 1983). In contrast, some investigations have shown that PGI2 is a
very potent stimulator of bone resorption in fetal rat long bone organ culture
(Dewhirst, 1984). Because PGI2 is formed by bone it may affect bone mineral
metabolism. PGI2 is a potent vasodilator and inhibitor of platelet aggregation
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(Navamani et al., 1997). Since blood vessels produce PGI2 it is possible that PGI2
release, perhaps augmented by the resident osteoblasts, may be responsible for the
frequent association between vascular invasion and resorption of bone or calcified
cartilage in physiologic remodeling and pathologic osteolysis (Raisz et al., 1979).
The pattern of PGF2α production in hOB cells on stimulation with cytokines
was similar to that of PGE2; its production was elevated a significant 25-fold by the
concurrent application of TGFβ and TNFα. This increase in PGF2α production after
cytokine stimulation suggests synergistic effects of TGFβ and TNFα over individual
administration of these cytokines in hOB cells, whose additive effects only reached
19.9 fold-basal. The synthesis of PGF2α was completely blocked by ibuprofen in
cells when administered along with the combination of TGFβ and TNFα. The basal
level of PGF2α in hOB cells was somewhat similar to that of 6-keto-PGF1α, although
it was only about 1/20th of the basal level of the most abundant PG, PGE2. These
results are in agreement with the previously published TLC data, which suggested
that PGF2α levels increased after stimulation with TGFβ and TNFα together (Xu et
al., 1997).
PGF2α is produced by bone cells, and exogenous PGF2α can stimulate bone
resorption (Raisz et al., 1990). Bone resorption was stimulated in mouse calvaria in
vitro by both PGE2 and PGF2α, each in a dose-dependent manner, with PGE2 being
more potent than PGF2α (Katz et al., 1981). PGF2α also effected bone formation in
contrast to the effects of PGE2 in cultured neonatal mouse parietal bones (Raisz et
al., 1990). Studies suggest that some of the effects of PGF2α on bone resorption,
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formation may be mediated by its capacity to stimulate an increase in endogenous
PGE2 production (Raisz et al., 1990).
PGD2 was the PG metabolite found in least amount in hOB cells; its
production was elevated by stimulation with TGFβ and TNFα, either individually or
in combination, in a similar pattern to that of the other prostaglandins measured.
Administration of TGFβ and TNFα in combination elevated the PGD2 levels to
about an 18-fold increase over basal and ibuprofen inclusion blocked the PGD2
formation stimulated by TGFβ and TNFα. PGD2 has a notable stimulatory activity
on alkaline phosphatase activity and osteoblast calcification, but the effective form
of PGD2 is probably a metabolite, ∆12-PGJ2 (Koshihara et al., 1989). ∆12-PGJ2
enhanced the transcription of type I procollagen (alpha 1) mRNA levels in
osteoblasts (Tasaki et al., 1991). It has been reported that PGJ2 and its derivatives
are effective activators of peroxisome proliferator-activated receptors alpha and
gamma (PPAR-∝ and PPAR- , respectively) (Kliewer et al., 1995). It has been
recently reported that nuclear hormone receptor peroxisome proliferator activated
receptor- , when activated, promotes adipogenesis and inhibits osteogenesis from
bone marrow progenitors (Nuttall et al., 2004). A bone-selective PPAR- modulator,
capable of acting as an antagonist, may be required to exploit PPAR- as a target for
osteoporosis therapy (Akune et al., 2004; Pei et al., 2004).
Prostaglandins are important mediators that play a multiple roles in biological
events, such as fever, pain, inflammation, tumorigenesis, gastrointestinal protection,
vascular circulation, and bone metabolism (Raisz, 1995; Kawaguchi et al., 1995;
Funk, 2001; Harris et al., 2002). Prostaglandin E2, PGF2α, and PGI2 are
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multifunctional regulators with both stimulatory and inhibitory effects on bone
formation and resorption (Raisz, 1995; Kawaguchi et al., 1995). The research
community has viewed the major effect of PGs as the stimulation of bone resorption
since PGE2 was first shown to increase cyclic AMP and stimulate resorption in
cultured fetal rat long bones more than 30 years ago (Klein and Raisz, 1970), but the
work of Jee and others has now identified PGE2 as an anabolic agent in bone as well
(Jee et al., 1985; Jee et al., 1987; Mori et al., 1990; Miller et al., 1994).
Prostaglandins exert versatile actions in diverse tissues and cells through
specific cell surface receptors. Molecular biological studies revealed the primary
structure of eight types of prostanoid receptor from various species. The prostanoids
act on the eight types and subtypes of the receptors. They are the PGD receptor (DP),
the EP1, EP2, EP3, and EP4 subtypes of the PGE receptor, the PGF receptor (FP), the
PGI receptor (IP), and the thromboxane A2 receptor (TP) (Samuelsson et al., 1978;
Moncada et al., 1985; Halushka et al., 1989; Coleman et al., 1990; Negishi et al.,
1995). These receptors can recognize the structural differences of prostanoid
molecules. The binding affinities of these receptors to prostanoid molecules are
determined primarily by the cyclopentane ring structures of ligands. For example,
the DP receptor shows the highest affinities to PGD2 and PGD1, but affinities to other
prostanoids are at least 2 orders of magnitude less. One exception is the IP receptor,
which shows an affinity to PGE1 almost comparable to PGI analogs such as iloprost.
This receptor, however, can bind PGE2 with much lower affinity, suggesting that the
IP receptor can discriminate a difference in the side chains. The term “Kd”
represents the affinity of a ligand for a particular receptor and it’s inversely related to
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receptor affinity. The activation of membrane receptors and target cell responses is
proportional to the degree of receptor occupancy.
The affinities of the prostanoid ligands for their specific receptors are as
follows: EP1 receptor subtype had a Kd value of 21 nM, EP2 receptor subtype had a
Kd value of 11 nM, EP3 receptor subtype had a Kd value of 3 nM, and the EP4
receptor subtype had a Kd value of 8.2 nM for radioligand [3H]PGE2 (Coleman et al.,
1994; Bastepe et al., 1997). Thus, a PGE2 response would be first seen with PGE2
binding the EP3 receptor subtype because it has Kd value of 3 nM for radioligand
[3H]PGE2. While other EP receptors would require greater amounts of PGE2 to be
come activated. The FP receptor type had Kd value of 1.3 nM for radioligand
[3H]PGF2α; IP receptor type had Kd value described as <10 nM for radioligand
[3H]6-keto PGF1α, and mouse DP receptor type had Kd value of 43 nM for
radioligand [3H]PGD2 (Coleman et al., 1994). Of the 8 receptors, EP4, EP1, EP2, EP3,
PGF2α (FPR), and PGI2 receptors have been found in bone and in osteoblastic cell
lines (Miyaura et al., 2000; Suzawa et al., 2000; Nemoto et al., 1995; Wang et al.,
1999).
The actions of prostaglandins produced by hOB cells will depend on the Kd
value for the prostanoid and its specific receptor. For example, the Kd value of the
EP3 receptor for PGE2 is 3 nM, and PGE2 production in hOB cells is approximately
27 nM. The FP receptor type has Kd value of 1.3 nM for radioligand PGF2α,
indicating that hOB cell production of PGF2α (~ 0.56 nM) should be sufficient to
activate the FP receptor population in bone. However, hOB cell culture model
doesnot exactly duplicate in vivo bone physiology, and the concentration of the PG

56

products in the microenvironment of the cells wouldn’t reflect the dilution by the cell
culture media, and should be rather higher.
15-HETE was also measured in hOB cell cultures by EIA. Its basal level, 0.5
ng/ml, was in the general range of 6-keto-PGF1α and PGF2α basal levels. TGFβ and
TNFα in combination elevated 15-HETE production in comparision to the levels
measured in specimens treated with either TGFβ or TNFα. 15-HETE production
was inhibited by the COX inhibitor ibuprofen. These results are in agreement with
thin layer chromatography (TLC) studies performed earlier in this laboratory, which
demonstrated a band that co-migrated with authentic 15-HETE in hOB cell
conditioned media, and that 15-HETE biosynthesis was eliminated in the presence of
the NSAIDs aspirin or ibuprofen (P.Keeting, personal communication). A band
tentatively identified as 12-HETE was also noted in the TLC studies, which appeared
unaffected by cytokine addition. These findings are not inconsistent with work that
showed that the amounts of all metabolites of lipoxygenases and cyclooxygenases
were decreased by aspirin or indomethacin pretreatment in the perfused hamster lung
tissue (Uotila et al., 1981; Schalin et al., 1982). However, typically the 15-LOX is
not viewed as an NSAID target.
The steady-state level of hOB cell 15-lipoxygenase-II mRNA was responsive
to modulation by TNFα, and by TGFβ plus TNFα in combination. TGFβ alone had
no demonstrable effect on 15-LOX-II mRNA levels in the hOB cells. Opposing
interaction effects for TGFβ and TNFα mediation of 15-lipooxygenase-II mRNA
expression in hOB cells was suggested, and when added concurrently TGFβ limited
the TNFα-mediated increase in 15-LOX-II mRNA levels.
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5-HETEs play an important role in bone research as suggested by studies on
the involvement of 5-HETEs in bone resorption by activating osteoclasts (Gallwitz et
al. 1993) and it might act as negative regulator of bone formation (Traianedes et al.,
1998). While our studies do not address the role of the 15-HETEs in hOB cells and
in bone remodeling, the identification 15-HETE production in hOB cells may serve
to stimulate investigations aimed at such topics. Thus, the roles of the 15-HETEs
and 15-LOX activity in bone remodeling and cellular signaling in osteoblasts is not
clear since their presence was not previously documented; however, since they are
produced in these cells, they may serve some mediator roles in bone remodeling, and
thus, in the etiology and progression of bone disorders such as osteoporosis.
However, it has been documented that 15-HETE has no proinflammatory capacity,
but that it can inhibit the formation and the chemotactic response of neutrophils to
leukotriene B4 (LTB4), a potent mediator of inflammation (Fogh et al., 1989). 15HETE inhibits carageenan-induced arthritis by lowering leukotriene B4
concentrations in the synovial fluid of dogs, indicating that it possesses antiinflammatory properties (Fogh et al., 1989).
Localized bone loss in rheumatoid arthritis results from the activation of an
inflammatory immune response, which increases both the number and the activity of
osteoclasts (Rehman et al., 2001). Elevated TNF-α levels can promote
osteoclastogenesis by stimulating the osteoblasts/stromal cells and possibly T
lymphocytes production of RANKL and M-CSF. In addition, recent in vitro studies
have shown that TNF-α, in the presence of M-CSF, directly induces the formation of
multinucleated cells containing tartrate-resistant acid phosphatase that are fully
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capable of resorbing bone (Azuma et al., 2000; Kobayashi et al., 2000). Several antiinflammatory cytokines such as IL-10, IL-11, and IL-13 act by suppressing the
production of inflammatory cytokines or by neutralizing them (Rehman et al., 2001).
15-HETE, because of its anti-inflammatory properties, may act by suppressing the
production of inflammatory cytokines or by neutralizing them and may play a
significant role in preventing bone loss.
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